SUMMARY A pilot study on 10 consecutive patients with newly diagnosed glaucoma and a randomised double-blind study on 18 patients with glaucoma were carried out to investigate the effect of pindolol, a beta-adrenergic blocking agent, on the intraocular pressure (IOP) in patients with glaucoma. The studies showed that pindolol may reduce the IOP and that no significant difference between the effect of timolol 0.5% and of pindolol 0.25% could be demonstrated. The serum concentration of pindolol was measured in 9 of the patients, but none had measurable serum levels.
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Most of the beta-adrenergic blocking agents have been investigated for their ability to reduce intraocular pressure.`3 Pindolol is a potent betaadrenergic blocking agent without a definite membrane-stabilising effect. 4 In other studies pindolol has proved able to reduce the IOP.
I It is therefore an interesting agent, deserving further study.
The two studies reported here were carried out at the Eye Clinic, Helsingborg Hospital, from 1979 to 1981. In the first study 10 consecutive patients with open-angle glaucoma were treated with pindolol eye drops for one month. The second study, which was of randomised, double-blind design, comprised 18 patients with open-angle glaucoma. Nine of the patients were treated with pindolol eye drops 0 25% and 9 with timolol eye drops 05%. All the patients were started on treatment with pindolol eye drops 0 25% twice daily. The same ophthalmologist measured the IOP by applanation tonometry 4 times daily (at 7.30 and. 11.00 a.m., and at 1.30 and 3.30 p.m.), according to the following schedule: (A) before starting treatment (day 0); (B) on the first day of treatment (day 1); (C) after 2 weeks of treatment (day 14); (D) after 4 weeks of treatment (day 28).
If the IOP was -22 mmHg after the treatment began the dose was raised to pindolol 0 5% twice daily, and, if it persisted, pilocarpine eye drops 4% were also given 3 times daily. To determine the pindolol serum level a blood sample was taken after one week of treatment, 20 minutes after instilling the drops. The serum level was measured by gas chromatography.'0 STUDY 2 Eighteen patients with open-angle glaucoma entered this randomised double-blind study. Patients with newly diagnosed glaucoma and patients receiving treatment with pilocarpine or adrenaline were included. None of the patients took a systemic betablocker. All the patients were treated for one month with either pindolol eye drops 0 25% twice daily or timolol eye drops 0 5% twice daily. Pilocarpine and adrenaline treatment was discontinued 3 days before these patients entered the study. The same ophthalmologist measured the IOP by applanation tonometry 4 times daily according to the following schedule: (A) before starting treatment (day 0); (B) on the first day of treatment (day 1); (C) after 4 weeks of treatment (day 28). If the IOP did not fall during the treatment, tonus was further measured, and in some cases 4% pilocarpine eye drops 3 times daily, were given.
The results were statistically evaluated by use of the analysis of variance. All statistical analyses are based on the values from only one of the patient's eyes. Where both eyes had been treated, the mean value was taken unless pilocarpine had been used in one eye, in which case the value from the eye treated solely with pindolol or timolol was used.
The studies were approved by the Ethical Committee, and the patients gave their written consent.
Results Fig. 1 shows the results of the pilot study. The mean curves are based on the results from 8 patients. The pilot study showed that pindolol eye drops reduced the pressure in all eyes treated. As with most of the other beta-adrenergic blocking agents, the reduction was marked on the first day of treatment but less as treatment continued.
Pilocarpine eye drops 4% were given 3 times daily as additional treatment to 3 eyes, 2 later required surgery. Before the start of treatment the IOP in these eyes had been 340 mmHg. The serum concentration of pindolol was not measurable and was therefore less than 10 ng/ml.
The randomised double-blind study comprised 18 patients, 4 of whom presented with glaucoma in only one eye. Fig. 2 shows the pressure-reducing effect of pindolol and timolol during 4 weeks of treatment. All eyes were treated with either pindolol eye drops 0 25% or timolol eye drops 0O5%. No significant difference could be demonstrated in the pressurereducing effect of the 2 preparations (p>>0»05).
Since the number of patients in the study is small the statistical power is somewhat limited. In previous studies timolol has been shown to reduce the intraocular pressure significantly better than placebo. " It may therefore be presumed that at least part of the fall in IOP may be ascribed to an effect of the 2 preparations.
Three patients (one receiving pindolol and 2 receiving timolol) experienced some irritation of the eye. Additional treatment with pilocarpine 4% was necessary in 3 eyes (2 timolol and 1 pindolol). The IOP in these eyes had been ¢40 mmHg before the start of treatment.
Discussion
The purpose of the pilot study and the randomised double-blind study was to investigate the effect of the beta-adrenergic blocking agent, pindolol, on IOP in the treatment of glaucoma. Both studies showed that pindolol eye drops reduced the IOP in glaucoma during the course of 4 weeks of treatment.
The double-blind study shows that both pindolol and timolol reduced IOP during 4 weeks of treatment. No significant difference between the effect of pindolol eye drops 0-25% and timolol eye drops 0 5% was found. Both preparations were well tolerated by all patients. The pressure-reducing effect of pindolol in long-term treatment and titration of the optimal concentration of pindolol eye drops need further study. 
